Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nitrous oxide abuse prevalence, mechanisms, treatments and prevention.

Current medical research and opinion·2026
Same author

Identification and Characterization of Mitragynine or 7-Hydroxymitraynine Oral Dosage Form Products That Appeal to Children.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

Contemporary Immunosuppression in Simultaneous Heart-Kidney Transplantation: A United Network for Organ-Sharing Database Analysis.

Pharmacotherapy·2026
Same author

Short-Term Care Burden After Left Ventricular Assist Device Implantation and Heart Transplant in the United States.

Journal of the American Heart Association·2026
Same author

Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.

The Annals of pharmacotherapy·2026
Same author

Nonswallowed Kratom-Derived Products: Unlawful Dietary Supplements That Endanger Public Health.

Public health reports (Washington, D.C. : 1974)·2026

Related Experiment Video

Updated: Jun 18, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Prasugrel: a critical comparison with clopidogrel.

Kurt M Reinhart1, C Michael White, William L Baker

  • 1Department of Pharmacy, Hartford Hospital, Hartford, Connecticut 06102, USA.

Pharmacotherapy
|December 2, 2009
PubMed
Summary
This summary is machine-generated.

Prasugrel, a potent thienopyridine antiplatelet drug, reduces cardiovascular events post-percutaneous coronary intervention compared to clopidogrel. However, it is associated with increased bleeding risk, requiring careful patient selection.

Related Experiment Videos

Last Updated: Jun 18, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Thienopyridine antiplatelet agents are crucial for preventing coronary stent thrombosis after percutaneous coronary intervention (PCI).
  • Ticlopidine and clopidogrel are established thienopyridines, with clopidogrel largely replacing ticlopidine due to improved potency and tolerability.

Purpose of the Study:

  • To evaluate the efficacy and safety of prasugrel, a newer thienopyridine, in patients undergoing PCI.
  • To compare prasugrel directly with clopidogrel in terms of cardiovascular event reduction and bleeding risk.

Main Methods:

  • A large-scale clinical trial comparing prasugrel and clopidogrel in patients undergoing PCI with stent placement.
  • Assessment of major adverse cardiovascular events (MACE) and major bleeding rates.

Main Results:

  • Prasugrel demonstrated a reduction in MACE compared to clopidogrel, attributed to its higher potency and faster onset of action.
  • Higher rates of major bleeding were observed with prasugrel compared to clopidogrel.
  • Prasugrel may exhibit fewer drug-drug interactions and less patient non-responsiveness, though further research is needed.

Conclusions:

  • Prasugrel is a promising antiplatelet option for patients with acute coronary syndromes undergoing PCI.
  • The increased potency of prasugrel offers significant cardiovascular benefits but necessitates careful consideration of bleeding risk.